Making monoclonal antibodies broadly accessible to communities most at risk of HIV/AIDS – What would it take?’
The Global HIV Vaccine Enterprise at the International AIDS Society and IAVI organised an online event to discuss challenges and opportunities on the Access to future monoclonal antibodies for HIV prevention.
The potential of monoclonal antibodies (mAbs) to treat and prevent infectious and neglected diseases is enormous. Although several mAbs targeting infectious diseases are licensed, there is a huge access gap, with 80% of the sale taking place in the US, Canada and Europe while 85% of the population at most risk of infectious diseases living in low- and middle- income countries. With a rapidly increasing pipeline of new mAb-based products for HIV and other infectious diseases, planning for how to bring these products to people that need them most is critical. IAVI has teamed with Wellcome to produce a report entitled Expanding Access to Monoclonal Antibody-based Products, with a call to action to the global health community to ensure equitable access to mAbs.
After decades of research and development a safe and globally effective HIV vaccine remains a challenge. However, new strategic approaches including passive immunisation, are in clinical development and may significantly contribute to HIV prevention strategies.
The Antibody Mediated Prevention study (AMP) aims to provide proof of concept for using a broadly neutralizing antibody (bNAb) to prevent HIV infection. Results from AMP are expected in late November early December.
For bnAbs to have an impact on the HIV epidemic, they must be developed and deployed in a manner that supports broad access globally.
The Webinar features an introduction from Mark Feinberg, CEO and President of IAVI, interviewed by Chloe Orkin, Clinical Professor of HIV Medicine at Queen Mary University of London, and chair of the British HIV Association (BHIVA), followed by perspectives of a renowned panel of experts on R&D, manufacturing, access, policy and regulation, and an audience Q&A. Panel includes:
- Mike Cohen, Director, Institute for Global Health and Infectious Diseases, UNC School of Medicine, USA.
- Helen Rees, Executive Director of the Wits Reproductive Health and HIV Institute at the University of the Witwatersrand, South Africa.
- Rosemary Mburu, Executive Director WACI Health, Kenya.
- Erin Sparrow, Technical Officer, Vaccine Product and Delivery Research Immunization, vaccines and Biologicals, World Health Organization, Geneva.
- Bill Snow,
- Co-Chair: Hester Kuipers (IAVI) and Roger Tatoud (Enterprise).
HIV vaccine: the search goes on!
An Enterprise Satellite at the AIDS 2020 Virtual Conference, 6-10 July 2020.
Biomedical prevention interventions have saved lives and helped prevent new HIV infections. However, declines in incidence remain far from UNAIDS targets. A safe and globally effective HIV vaccine remains a necessity for a durable control and end to the epidemic. Diverse and promising HIV vaccines candidates are in various stages of development and exciting results from vaccine efficacy and passive immunization trials are expected in the coming years. The vaccine field remains hopeful and determined – even with the necessary shift in attention to developing SARS-CoV-2 control measures. Communicating the wealth and breadth of ongoing research, and the steadfast commitments of funders, researchers, product developers and communities to find a vaccine remains critically important. Co-sponsored by the Enterprise, NIH/HVTN/HPTN, with the participation of the South African Medical Research Council, IAVI, EU consortiums and AVAC, this satellite will showcase current HIV vaccine research and development.
HIV Vaccines & Prophylactic Biologics Development
7 July 2019.
In this presentation at the AIDS 2020 Virtual Conference, Dr. Nina Russell gives an overview of the Bill and Melinda Gates Foundation strategies and priorities. (COMMIND SOON)
HIV Vaccines: Moving Ahead in the times of COVID-19
7 July 2019.
Dr. Carl Dieffenbach of the NIH Division of AIDS, gives an opening remark to the Enterprise sponsored satellite “HIV vaccine: The search goes on!” at the AIDS 2020 Virtual Conference. (COMMIND SOON)
Established in 2003, the Global HIV Vaccine Enterprise (the Enterprise) became a programme of IAS – the International AIDS Society – in 2018. The Enterprise unites stakeholders to share knowledge, foster collaboration, enable solutions and expand support critical to the development of – and future access to – an HIV vaccine.
Global HIV Vaccine Enterprise
IAS – the International AIDS Society
Avenue de France 23